Davies HD, Sakuls P, Keystone JS: Creeping eruption. .Arch Dermatol 129::588. ,1993. .
Albanese G, Venturi C, Galbiati G: Treatment of larva migrans cutanea (creeping eruption): a comparison between albendazole and traditional therapy. .Int J Dermatol 40::67. ,2001. .
Little MD, Halsey NA, Cline BL, et al: Ancylostoma larva in a muscle fiber of man following cutaneous larva migrans. .Am J Trop Med Hyg 32::1285. ,1983. .
Biolcati G, Alabiso A: Creeping eruption of larva migrans: a case report in a beach volley athlete. .Int J Sports Med 18::612. ,1997. .
Caumes E: Treatment of cutaneous larva migrans. .Clin Infect Dis 30::811. ,2000. .
Silverberg NB, Jackson RM, Laude TA, et al: Picture of the month. .Arch Fam Med 7::403. ,1998. .
Hotez PJ, Narasimhan S, Haggerty J, et al: Hyaluronidase from infective Ancylostoma hookworm larvae and its possible function as a virulence factor in tissue invasion and in cutaneous larva migrans. .Infect Immun 60::1018. ,1992. .
Nakamura-Uchiyama F, Yamasaki E, Nawa Y: One confirmed and six suspected cases of cutaneous larva migrans caused by overseas infection with dog hookworm larvae. .J Dermatol 29::104. ,2002. .
Caumes E: Treatment of cutaneous larva migrans and Toxocara infection. .Fundam Clin Pharmacol 17::213. ,2003. .
Caumes E, Carriere J, Datry A, et al: A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. .Am J Trop Med Hyg 49::641. ,1993. .
Cutaneous larva migrans is a common skin pathology that occurs in people who have recently visited tropical or subtropical climates. Given the ubiquity of this condition, the podiatric physician may encounter cutaneous larva migrans during clinical practice and should be cognizant of the presenting signs and typical patient history given in these cases. We describe the case of a 62-year-old man who presented with a pruritic, erythematous, serpiginous lesion on the dorsum of his left foot after having vacationed in Florida for several weeks. The patient was treated successfully with oral thiabendazole, 500 mg after meals 4 times daily for 5 days. (J Am Podiatr Med Assoc 95(3): 291–294, 2005)